ROEDER DOUGLAS A purchased $125K of SENS

Senseonics Holdings has started the first human trial for its Freedom CGM system, which transmits data directly to mobile devices without an external transmitter. The trial focuses on safety and functionality, with plans for a pivotal trial in 2027 and potential commercial release in 2028. The device builds on the Eversense 365 system, aiming to eliminate external components. Preclinical assessments were completed in Q2 2026.

Barclays initiated coverage on 26 medical device makers, rating Stryker (SYK) and Abbott Laboratories (ABT) as Overweight. Analyst Christopher Pasquale cited compelling valuations and a potential stabilization of revenue as catalysts. Price targets were set for several companies, including SYK at $375 and ABT at $120.

Beta Bionics (BBNX) received FDA clearance for its Mint patch pump, aiming for a Q1 2027 U.S. launch. The company also unveiled 3D Intelligence, a next-gen insulin dosing algorithm. Beta Bionics lowered its 2026 revenue outlook to $121M-$126M, citing potential revenue deferral. A partnership with Senseonics (SENS) was announced for integrating Eversense 365 with iLet Bionic Pancreas.

Senseonics Holdings, Inc. (SENS) filed an SEC Form 8-K — Results of Operations and Financial Condition. ​ Senseonics Holdings, Inc. Reports Second Quarter 2026 Financial Results ● Generated second quarter revenue of $14.5 million, an increase of approximately 120% year-over-year ● Raising full-year 2026 revenue guidance to $62 million to $66 million from $60 million to $64 million,

Haggart Dylan G. purchased 154,196 indirectly-held shares of Stride, Inc. (LRN) at an average of $78.98 ($78.44–$79.84, $12.18M total) across 3 trades over 2026-10-23 to 2026-10-26. Filed jointly with Fivespan Partners, LP.

AKKARAJU SRINIVAS purchased 289,470 indirectly-held shares of Scholar Rock Holding Corp (SRRK) at an average of $41.45 ($41.31–$41.82, $12.00M total) across 6 trades over 2026-10-23 to 2026-10-26.